MedDataX Logo

Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients

NCT ID: NCT01853839

Last Updated: 2015-08-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1674 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an out-patient based prospective, multi-centre, observational post-marketing surveillance study amongst internists and cardiologists. In this study, patients with essential hypertension and at least one additional risk factor will be included. Patients may take any antihypertensive treatment which is approved for cardiovascular protection including Micardis 80 mg / Micardis Plus. Patients will be followed over one year in four visits from baseline to endpoint with an additional visit before and after the month of Ramadan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives

NCT04357535

COVID-19
COMPLETED

Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure

NCT00925470

Blood Pressure
COMPLETED

Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension

NCT00971165

Hypertension Cardiovascular Disease
COMPLETED PHASE3

Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension

NCT00380289

Essential Hypertension
UNKNOWN NA

Evaluation of Target Organs Damage in Hypertensive Patients

NCT01055353

Target Organs Damage Hypertensive no Known Cardiovascular +1 more
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Purpose:

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female of age 18 years or older;
2. Newly diagnosed and untreated or previously treated and uncontrolled patients with essential hypertension;
3. Seated blood pressure of \>140/90 mmHg or \>130/80 mmHg in patients with diabetes mellitus or chronic kidney disease;
4. Patients with at least one cardiovascular (cv) risk factor;
5. Ability to provide written informed consent.

Exclusion Criteria

1. Patients with contraindications to the prescribed antihypertensive medications;
2. Pregnant or lactating women or women of childbearing potential not using an acceptable method of contraception;
3. Patients who are participating in any other study protocol.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 106

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 107

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 108

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 109

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 110

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 111

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 112

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 113

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 114

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 115

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 116

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 117

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 118

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 119

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 120

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 121

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 122

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 123

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 124

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 125

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 126

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 127

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 128

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 129

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 130

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 131

Algiers, , Algeria

Site Status

Boehringer Ingelheim Investigational Site 29

Al Fayyum, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 15

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 19

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 21

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 22

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 23

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 3

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 6

Alexandria, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 18

Asyut, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 27

Asyut, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 11

Banisuif, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 10

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 12

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 13

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 14

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 17

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 1

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 20

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 24

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 25

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 26

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 28

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 2

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 4

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 5

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 7

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 8

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 9

Cairo, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 30

Domiat, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 16

Menia, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 31

Tanta, , Egypt

Site Status

Boehringer Ingelheim Investigational Site 66

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 67

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 68

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 69

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 70

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 71

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 72

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 73

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 74

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 75

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 76

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 77

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 78

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 79

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 80

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 81

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 82

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 83

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 84

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 85

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 86

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 87

Beirut, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 88

Tripoli, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 89

Tripoli, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 90

Tripoli, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 91

Tripoli, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 92

Tripoli, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 93

Tripoli, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 94

Tripoli, , Lebanon

Site Status

Boehringer Ingelheim Investigational Site 35

Dammam, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 36

Dammam, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 37

Dammam, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 38

Hofuf, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 50

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 51

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 52

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 53

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 54

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 55

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 56

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 57

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 58

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 59

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 60

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 61

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 62

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 63

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 64

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 65

Jeddah, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 32

Khobar, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 33

Khobar, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 34

Khobar, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 105

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 39

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 40

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 41

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 42

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 43

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 44

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 45

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 46

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 47

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 48

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 49

Riyadh, , Saudi Arabia

Site Status

Boehringer Ingelheim Investigational Site 100

Dubai, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 101

Dubai, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 102

Dubai, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 103

Dubai, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 104

Dubai, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 132

Dubai, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 95

Sharjah city, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 96

Sharjah city, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 97

Sharjah city, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 98

Sharjah city, , United Arab Emirates

Site Status

Boehringer Ingelheim Investigational Site 99

Sharjah city, , United Arab Emirates

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Algeria Egypt Lebanon Saudi Arabia United Arab Emirates

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.602

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Japan Morning Surge-1 Study
NCT00285519 COMPLETED PHASE4
Egypt Hypertension Study
NCT02604771 COMPLETED
Nesiritide in Hypertension
NCT02608996 RECRUITING PHASE1/PHASE2
Oral Sodium Blood Pressure in Normal Weight, Overweight and Obese Volunteers
NCT01532401 COMPLETED PHASE2
Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension
NCT04753840 RECRUITING NA
Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects
NCT03001271 UNKNOWN EARLY_PHASE1
Effects of Romadan Fasting on Variability in Blood Pressure in Healthy and Hypertensive Subjects
NCT05152043 COMPLETED
Nocturnal Blood Pressure Dipping and Ventricular Repolarization in Hypertension
NCT07200856 NOT_YET_RECRUITING
Hypertension Prevention in Pre-Hypertensive Individuals
NCT00970931 COMPLETED PHASE3
Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients
NCT04554069 UNKNOWN
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
NCT00387621 COMPLETED PHASE1/PHASE2
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression
NCT00518479 COMPLETED NA
Blood Pressure and Diurnal Variation in Sodium, Potassium, and Water Excretion
NCT00005204 COMPLETED
The Effect of Sodium Reduction on Blood Pressure and Physical Function in Older Adults
NCT04074941 COMPLETED NA
Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives
NCT04531124 NOT_YET_RECRUITING
Pulmonary Artery Pressure in COVID-19 Survivors
NCT05993338 COMPLETED NA
Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)
NCT04040634 ACTIVE_NOT_RECRUITING NA
B-type Natriuretic Peptide (BNP) in Human Hypertension
NCT00953472 TERMINATED PHASE1
Impact of Intravenous Methylprednisolone Treatment on Blood Pressure
NCT03590080 COMPLETED
Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension
NCT00353652 COMPLETED PHASE4
Effects of Intensive Systolic Blood Pressure Lowering Treatment on Out-of-office Blood Pressure - an Ancillary Study to Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing RIsk of Vascular evenTs (ESPRIT) Study
NCT05352633 UNKNOWN NA
Analysis of Antihypertensive Treatment Efficacy
NCT00767247 TERMINATED
Effect of Antihypertensive Agents Over Sleep Apnea
NCT01896661 COMPLETED PHASE3
Emerging Biomarkers in Hypertension
NCT02064218 UNKNOWN
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin
NCT03553303 UNKNOWN PHASE4